05-07-2012: The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).
On 2 September 2011, Janssen-Cilag International NV submitted an application to extend the marketing authorisation for Velcade in combination with rituximab for the treatment of patients with relapsed follicular non-Hodgkin lymphoma. At the time of the withdrawal the application was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).
Velcade was first authorised in the European Union on 26 April 2004 and is indicated in combination with melphalan and prednisone to treat patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with a bone marrow transplant. Velcade is also indicated as monotherapy to treat progressive multiple myeloma in patients who have received at least one prior therapy and have already had or are unsuitable for a bone marrow transplant. In its official letter, the company stated that it decided to withdraw the application after the CHMP indicated that the data provided do not support a positive benefit-risk balance.
Velcade continues to be authorised in the currently approved indications.
The European Medicines Agency (EMA) has been ordered by the General Court of the European Union not to provide documents as part of two access-to-documents requests until a final ruling is given by the Court. These interim rulings were made as part of court cases brought by two pharmaceutic ... more
Following the recent recommendation by the Pharmacovigilance Risk Assessment Committee (PRAC), the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) has endorsed by majority the PRAC recommendation to suspend the marketing authorisations of tetrazepam-co ... more
The European Medicines Agency has published its 2012 annual report. The report highlights the main trends recently observed in the Agency’s activities. For the past few years, the Agency has received a stable number of initial marketing authorisation applications (MAAs) for human medicines, ... more
The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. more
The European Medicines Agency has been formally notified by Janssen-Cilag International NV of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorised medicine Velcade (bortezomib).On 2 September 2011, Janssen-Cilag International N ... more
Basilea Pharmaceutica Ltd. announces that Janssen-Cilag AG, a Johnson & Johnson company, will be discontinuing sale of ceftobiprole (Zevtera(TM)) for the treatment of complicated skin and soft tissue infections (cSSTI) in Switzerland.
Janssen-Cilag AG, the holder of the Marketing Authoriza ... more
Basilea Pharmaceutica Ltd. announces that following a request for re-examination from the Applicant Janssen-Cilag International NV, a Johnson & Johnson company, the European Committee for Medicinal Products for Human Use (CHMP) confirmed its previous negative opinion on the Marketing Author ... more
Janssen-Cilag develops and markets innovative, high-quality pharmaceutical products and services aimed at improving quality of life for people with medical needs across the world.
We view ourselves as a full-service partner for all stakeholders in healthcare, as evidenced in the first line ... more